Saturday June 2 Press Briefing: ASCO Press Releases with links to abstracts

Matching Treatment to Genetic Changes in the Tumor Improves Survival Across Multiple Cancer Types

Summary includes updated data not in the abstract 

 “It’s been 20 years since the first targeted therapy was introduced. These first ‘precision medicine’ therapies revolutionized cancer care and helped many patients live longer. But we’ve just scratched the surface. Now with faster and more robust genetic tests, we can help even more patients by treating the cancer based on its genetic makeup rather than solely on its location in the body,” said ASCO Expert Catherine Diefenbach, MD. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Genomic Study Finds Lynch Syndrome Is Common Among People With MSI-High Tumors

 “This study enhances our ability to catch Lynch syndrome where it may have been previously overlooked, thanks in large part to advances in precision medicine. This gives us a valuable opening to preempt future cancers in our patients through better, earlier, and more accurate diagnosis of Lynch syndrome,” said ASCO Expert Shannon Westin, MD. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Adding Atezolizumab Immunotherapy to Chemotherapy Slows Growth of Advanced Squamous Lung Cancer

“This is one more example of how immunotherapy is making steady gains against a number of cancers. Immunotherapy has been shown to be effective in other types of lung cancer, and now we’re seeing encouraging improvements in advanced squamous lung cancer, which historically has been very difficult to treat,” said ASCO Expert David Graham, MD, FASCO. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Blood Test Shows Potential as a Detection Tool for Early-Stage Lung Cancer

Summary includes updated data not in the abstract 

“We’re one step closer to being able to detect early lung cancer from a simple blood test. While there’s still a way to go before cell-free DNA from blood can be used for cancer detection on a broad scale, this research serves as a building block for the development of future tests,” said ASCO Expert David Graham, MD, FASCO. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

See also Abstracts 536, 12003 & 12021 mentioned in the ASCO press release

 

New Targeted Therapy Slows Growth of Advanced Breast Cancer

“We now know that it’s possible to target this common breast cancer mutation, and it’s heartening to see that a new therapy can provide some benefits to women with advanced breast cancer. However, because the treatment has side effects, doctors will have to weigh its benefits and risks with their patients,” said ASCO Expert Harold Burstein, MD, PhD, FASCO. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT